免疫检查点抑制剂治疗晚期肝癌的研究进展

Research progress of immunocheckpoint inhibitors in treatment of advanced liver cancer

肝癌具有高发病率和病死率,已严重危害人类健康,并且肝癌发病隐匿,发现时多为晚期,因此多数患者失去手术切除时机。肝癌治疗历经多种方式,目前免疫治疗的研究逐步深入,其在晚期肝癌的Ⅰ、Ⅱ期临床试验获得较好的疗效。本文就免疫检查点抑制剂单独或结合其他方式治疗晚期肝癌,免疫检查点抑制剂真实世界研究及治疗效果预测物的进展进行综述,为临床使用免疫检查点抑制剂提供参考,并为免疫检查点抑制剂的进一步研究提供依据。

With high morbidity and fatality,liver cancer has seriously harmed human health.The onset of liver cancer is insidious,and the discovery time is usually late,so most patients lose the opportunity of surgical resection.The treatment of liver cancer through a variety of ways,the current immunotherapy is gradually in-depth,and its clinical trials in advanced liver cancerⅠ,Ⅱperiod has obtained a better curative effect.This paper reviews the progress of immunocheckpoint inhibitors alone or in combination with other methods in the treatment of advanced liver cancer,the real world studies of immunocheckpoint inhibitors and the predictors of therapeutic effect,for providing a reference for the clinical use of immunocheckpoint inhibitors,and providing a basis for the further study.